JP2681244B2 - Analytical method for urinary dissolved components - Google Patents
Analytical method for urinary dissolved componentsInfo
- Publication number
- JP2681244B2 JP2681244B2 JP5005675A JP567593A JP2681244B2 JP 2681244 B2 JP2681244 B2 JP 2681244B2 JP 5005675 A JP5005675 A JP 5005675A JP 567593 A JP567593 A JP 567593A JP 2681244 B2 JP2681244 B2 JP 2681244B2
- Authority
- JP
- Japan
- Prior art keywords
- urine
- sample
- dissolved components
- acid
- analyzing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004458 analytical method Methods 0.000 title claims description 6
- 230000002485 urinary effect Effects 0.000 title 1
- 210000002700 urine Anatomy 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims description 5
- 108010075254 C-Peptide Proteins 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000002222 fluorine compounds Chemical class 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
【０００１】[0001]
【産業上の利用分野】この発明は、尿試料中の溶存成分
が分解や細菌等による変性により量が変化するのを防止
しつつ尿試料を保存し、その後、尿中溶存成分の分析測
定を行う分析測定方法に関し、種々の内臓疾患の兆候や
程度を分析するときに用いられる。This invention relates to the storage of urine samples while preventing the amount of dissolved components in urine samples from changing due to decomposition or denaturation by bacteria, etc. Regarding the analytical measurement method to be performed, it is used when analyzing signs and degrees of various visceral diseases.
【０００２】[0002]
【従来の技術】最近の病理学の進歩によって尿中の溶存
成分，例えばＣーペプチド，アルブミン，グリシン，尿
素等の量を測定することは腎臓，尿路系，肝臓，先天性
疾患，悪性腫瘍を診断する上で非常に重要な臨床検査対
象となってきた。ところが採取した尿試料を室温で放置
すると尿中の溶存成分は細菌による変性，分解，産生に
より，それぞれ減少或いは増加することが知られてい
る。2. Description of the Related Art Due to recent advances in pathology, measuring the amount of dissolved components in urine, such as C-peptide, albumin, glycine, urea, etc., is effective in measuring renal, urinary tract, liver, congenital diseases and malignant tumors. It has become a very important clinical test subject for diagnosis. However, it is known that when the collected urine sample is left at room temperature, the dissolved components in urine decrease or increase due to denaturation, decomposition, and production by bacteria.
【０００３】尿の試料を採取する場合に，適時に採取し
て各尿試料を検査試料として用いる逐次尿法と一日（２
４時間）の尿を蓄積して混合してその一部を試料として
用いる蓄尿法がある。その各々の方法について従来から
前記の溶存成分の変性，減少，増加を抑制する方法とし
て以下の方法が提案されている。In the case of collecting urine samples, a sequential urine method in which each urine sample is used as a test sample by collecting it in a timely manner (2
There is a urine storage method in which urine for 4 hours) is accumulated and mixed, and a part of it is used as a sample. For each of the methods, the following methods have been conventionally proposed as methods for suppressing the denaturation, decrease and increase of the above-mentioned dissolved components.
【０００４】逐次尿法の場合において (1) 耐薬性の容器にトルエンまたはキシロールを 0.05
ml／ml (尿１ml当たり）トルエン 0.05 mlを加える。 (2)クロロホルム溶液を 0.05 ml／10 ml 加える。 (3)１２規定の塩酸を 0.1 ml ／10 ml 加える。 (4)低温室に入れて低温保存する。In the case of the sequential urine method (1) Toluene or xylol was added to a drug-resistant container in an amount of 0.05
ml / ml (per 1 ml of urine) Add 0.05 ml of toluene. (2) Add 0.05 ml / 10 ml of chloroform solution. (3) Add 0.1 ml / 10 ml of 12N hydrochloric acid. (4) Place in a low temperature room and store at low temperature.
【０００５】蓄尿法の場合には (1)トルエンまたはキシロールを５ml／ｌ加え，時々震
盪混和する。 (2)中性ホルマリンを５〜10ml／ｌ加える。 (3)クロルヘキシジンの５％溶液を５ml／ｌ加える。 (4)市販のほう酸またはパラホルムアルデヒド錠剤を加
える。 (5)１２規定塩酸を10ml／ｌ加える。 (6)低温室に入れて低温保持する。 等で,(1)〜(5) は防腐剤を加えるものであり，(6) は低
温保持するものである。In the case of the urine storage method, (1) 5 ml / l of toluene or xylol is added, and occasionally mixed by shaking. (2) Add 5 to 10 ml / l of neutral formalin. (3) Add 5 ml / l of a 5% solution of chlorhexidine. (4) Add commercially available boric acid or paraformaldehyde tablets. (5) Add 10 ml / l of 12N hydrochloric acid. (6) Put in a low temperature room and keep low temperature. Etc., (1) to (5) are for adding preservatives, and (6) are for keeping at low temperature.
【０００６】[0006]
【発明が解決しようとする課題】しかし前記の従来の方
法では，尿採取直後に薬剤を混合する作業が厄介であ
り，また低温に保持する方法は試料を輸送，貯蔵するこ
とが厄介であるという理由で実際には用いられていな
い。However, in the above-mentioned conventional method, it is difficult to mix the drugs immediately after collecting urine, and in the method of keeping the temperature low, it is difficult to transport and store the sample. Not actually used for any reason.
【０００７】例えば逐次尿に対する (1)，(2) の方法，
蓄尿に対する (1)〜(3) の方法では耐薬性の容器を使用
する必要があり，且つ使用する薬剤が測定に使用する試
薬に影響して測定不能となる成分が多い。また逐次尿に
対する (1)〜(3),蓄尿に対する (1)〜(5) の方法では人
体に強い毒性を有する薬剤を用いるので危険性が高いと
いう課題がある。For example, the methods (1) and (2) for sequential urine,
The methods (1) to (3) for storing urine require the use of a drug-resistant container, and the drug used influences the reagent used for measurement, and many components cannot be measured. In addition, the methods (1) to (3) for sequential urine and (1) to (5) for accumulated urine have a problem of high risk because a drug having strong toxicity to the human body is used.
【０００８】尿中の溶存成分が変性，減少あるいは増加
する原因は尿中に常在あるいは病的に存在する細菌が繁
殖し生命活動を営むために代謝活動その他の活動をする
ことにより発生する。現在では厄介な手間をかけずにこ
のような細菌の活動を阻止し，且つ多くの成分の測定に
対して障害とならず，安全な尿試料の保存方法がないと
いう課題があった。The cause of denaturation, decrease or increase of dissolved components in urine is caused by the fact that bacteria resident or pathologically present in urine reproduce and carry out life activity, thereby performing metabolic activity and other activities. At present, there has been a problem that the activity of such bacteria can be prevented without troublesome work, the measurement of many components is not hindered, and there is no safe storage method for a urine sample.
【０００９】[0009]
【課題を解決するための手段】前記の実状に鑑み本発明
者らは鋭意研究の結果，本発明者らの特願平２ー９０６
３８号，特願平４ー４８１５６号「尿中の細胞保存方
法」として出願した試料尿の保存方法を適用すると，尿
中の溶存成分の変性，減少，増加を防止することができ
ることを発見して本発明をなしたものである。In view of the above-mentioned circumstances, the inventors of the present invention have conducted intensive studies and as a result, have filed a patent application No. 2-906 of the present inventors.
No. 38, Japanese Patent Application No. 4-48156, "Method for preserving cells in urine", it was discovered that application of the method for preserving sample urine can prevent denaturation, decrease and increase of dissolved components in urine. The present invention has been made.
【００１０】すなわち本発明は、尿中の溶存成分である
Ｃ−ペプチド、アルブミン、グリシン、尿素、ブドウ糖
などを分析測定するに際して、採取した試料尿に各種酸
を加えてｐＨを４．５〜６．５に調整して微生物の代
謝、増殖を抑制し、さらに抗菌性薬剤であるＥＤＴＡを
添加すると共に、フッ素化合物を等量換算でＮａＦを尿
１ｍ１当たり１ｍｇ以上添加して微生物の増殖などの生
活活動を抑制して溶存成分の変性、減少、増加を阻止し
て尿中溶存成分の分析測定を行う。That is, according to the present invention, when the dissolved components in urine such as C-peptide, albumin, glycine, urea and glucose are analyzed and measured, various acids are added to the collected sample urine to adjust the pH to 4.5 to 6. In addition to adding EDTA, which is an antibacterial drug, to suppress the metabolism and growth of microorganisms by adjusting to 0.5, and adding 1 mg or more of NaF in an equivalent amount of fluorine compound per 1 m1 of urine to life such as growth of microorganisms. Suppress activity to prevent denaturation, decrease, and increase of dissolved components, and analyze and measure dissolved components in urine.
【００１１】[0011]
【作用】尿のｐＨは通常 4.5〜10.0と広い範囲である
が, 本発明においては酸を緩衝剤として加えて試料尿が
4.5〜6.5 と酸性になるように調整する。酸としては無
機酸, 有機酸のいずれでも良い。特にクエン酸は粉末状
として予め採取管に投入しておくことができるので便利
である。The pH of urine is usually in a wide range of 4.5 to 10.0, but in the present invention, the sample urine is added by adding an acid as a buffer.
Adjust so that it becomes acidic at 4.5 to 6.5. The acid may be either an inorganic acid or an organic acid. In particular, citric acid is convenient because it can be put into the collection tube in advance as a powder.
【００１２】抗菌性薬剤としてＥＤＴＡ・２Ｎａを用い
ると尿中の溶存成分の保存効果が向上する。その場合に
ＥＤＴＡ・２Ｎａを０．４〜４．０ｍｇ／ｍｌ（尿当た
り）の量で実効を有する。The use of EDTA.2Na as an antibacterial agent improves the effect of preserving dissolved components in urine. In that case, EDTA.2Na is effective at an amount of 0.4 to 4.0 mg / ml (per urine).
【００１３】フッ素化合物は微生物の増殖抑制剤および
抗菌剤としてしられているが, 尿のｐＨを低下させた条
件下では, 等価換算でＮａＦを尿１ml当たり１mg以上の
濃度になるように添加すると初めてフッ素化合物が細菌
をはじめとする微生物の増殖抑制作用が有効に発揮され
る。Fluorine compounds are known as growth inhibitors and antibacterial agents for microorganisms, but under the condition that pH of urine is lowered, if equivalent NaF is added to a concentration of 1 mg or more per 1 ml of urine, For the first time, the fluorine compound effectively exerts the effect of suppressing the growth of microorganisms such as bacteria.
【００１４】本発明を実施するにはクエン酸，ＥＤＴＡ
・２Na，ＮａＦを顆粒状製剤或いは凍結乾燥製剤とし，
それを混合した薬剤を尿採取管に予め規定量だけ投入し
ておき，それに尿を規定量採取し，そのまま保存して溶
存成分の分析，測定を行えばよい。To carry out the present invention, citric acid, EDTA
・ 2Na and NaF in granular or freeze-dried form,
A prescribed amount of the mixed drug is put in a urine collection tube in advance, a prescribed amount of urine is sampled, and stored as it is for analysis and measurement of dissolved components.
【００１５】[0015]
【実施例】試料採取管（試験管）に尿を採取して，クエ
ン酸４mg／ml (尿当たり) , ＥＤＴＡー２Naを３mg／ml
(尿当たり) およびＮａＦを１mg／ml (尿当たり) を添
加して混合した。用いた尿のｐＨは 6.6であり, 添加後
はｐＨは 5.0となった。[Examples] Urine was collected in a sample collection tube (test tube), and citric acid 4 mg / ml (per urine) and EDTA-2Na 3 mg / ml
(Per urine) and NaF at 1 mg / ml (per urine) were added and mixed. The pH of the urine used was 6.6, and the pH after addition was 5.0.
【００１６】この尿試料を２６℃に保存して１２時間毎
のＣーペプチド，アルブミン，グリシン，尿素，および
ブドー糖の量を測定し０時（初期）の値と比較評価した
ところ，４８時間後までは変化が起こらなかった。９６
時間後でもＣーペプチドでは５％，グリシンは７％しか
低下せず，アルブミン，尿素，ブドー糖には変化がなか
った。This urine sample was stored at 26 ° C., and the amounts of C-peptide, albumin, glycine, urea, and budo sugar were measured every 12 hours, and compared and evaluated with the value at 0 hour (initial). After 48 hours, Until then there was no change. 96
Even after the lapse of time, C-peptide was decreased by 5% and glycine was decreased by 7%, and albumin, urea, and glucose were unchanged.
【００１７】[0017]
【発明の効果】以上に詳しく説明したように、本発明
は、尿中の細菌を始めとする微生物の増殖、生活活動を
抑制して尿試料中の溶存成分を保存しており、簡単な方
法でありながら、試料採取後の分析測定までに数十時間
試料を保存しても正確な測定値が得られる。それ故、尿
中の溶存成分の検査、測定、特に大量の尿試料を検査、
測定する場合に大きな効果を発揮する。INDUSTRIAL APPLICABILITY As described above in detail, according to the present invention, the dissolved components in a urine sample are preserved by suppressing the growth and living activities of microorganisms such as bacteria in urine, which is a simple method. However, an accurate measurement value can be obtained even if the sample is stored for several tens of hours before the analysis measurement after sampling. Therefore, the examination and measurement of dissolved components in urine, especially the examination of large urine samples,
It is very effective when measuring.
Claims (4)
ルブミン、グリシン、尿素、ブドウ糖などを分析測定す
るに際して、採取した試料尿に各種酸を加えてｐＨを
４．５〜６．５に調整すると共に、抗菌性薬剤と、等量
換算でＮａＦが尿１ｍｌ当たり１ｍｇ以上となるフッ素
化合物とを添加して試料尿を保存することを特徴とする
尿中溶存成分の分析測定方法。1. A C-peptide, which is a dissolved component in urine,
Analyzing and measuring rubumin, glycine, urea, glucose, etc.
Runisaishite, together with various acid was added to the collected sample urine pH is adjusted to 4.5-6.5, and antimicrobial agents, eq
Fluorine that converts NaF to 1 mg or more per 1 ml of urine
Characterized by adding a compound and preserving the sample urine
Method for analysis and measurement of dissolved components in urine .
する請求項１記載の尿中溶存成分の分析測定方法。2. The method for analyzing and measuring dissolved components in urine according to claim 1, wherein citric acid is used as the acid.
０．４〜４．０ｍｇ／ｍｌ（尿当たり）混合することを
特徴とする請求項１もしくは２記載の尿中溶存成分の分
析測定方法。3. The urine-dissolved component according to claim 1 or 2, wherein EDTA · 2Na is mixed as an antibacterial agent in an amount of 0.4 to 4.0 mg / ml (per urine).
Analysis method .
Ａ・２Ｎａ、ＮａＦを適量に混合した薬剤を投入してお
き、該試料採取管に規定量の尿を採取して得られた尿試
料をそのまま保存することを特徴とする請求項１〜３い
ずれかに記載の尿中溶存成分の分析測定方法。4. Granular citric acid, EDT in a sampling tube
4. A urine sample obtained by collecting a prescribed amount of urine into the sample collection tube and storing the urine sample as it is, by introducing a drug containing A.2Na and NaF mixed in appropriate amounts. The method for analyzing and measuring dissolved components in urine according to Crab.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5005675A JP2681244B2 (en) | 1993-01-18 | 1993-01-18 | Analytical method for urinary dissolved components |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5005675A JP2681244B2 (en) | 1993-01-18 | 1993-01-18 | Analytical method for urinary dissolved components |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06213885A JPH06213885A (en) | 1994-08-05 |
| JP2681244B2 true JP2681244B2 (en) | 1997-11-26 |
Family
ID=11617680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5005675A Expired - Fee Related JP2681244B2 (en) | 1993-01-18 | 1993-01-18 | Analytical method for urinary dissolved components |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2681244B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5423893A (en) * | 1992-06-18 | 1995-06-13 | Kotaki; Daizo | Plastic filter, its injection molding die and producing method |
| US5650181A (en) * | 1993-06-17 | 1997-07-22 | Kotaki; Daizo | Injection molding die for producing plastic filter |
| JP3592822B2 (en) * | 1996-01-23 | 2004-11-24 | 株式会社いかがく | Method for storing collected urine and kit for collecting urine |
| JP6355149B1 (en) * | 2016-12-19 | 2018-07-11 | 株式会社ユカシカド | Urine test apparatus and urine test method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0778502B2 (en) * | 1990-04-04 | 1995-08-23 | 株式会社京都医科学研究所 | Method for preserving cells in urine |
-
1993
- 1993-01-18 JP JP5005675A patent/JP2681244B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06213885A (en) | 1994-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Piga et al. | High nontransferrin bound iron levels and heart disease in thalassemia major | |
| Patel et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin | |
| Glazko et al. | An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects | |
| US4780419A (en) | Method of inhibiting glycolysis in blood samples | |
| Skov | Glomerular filtration rate in patients with severe and very severe renal insufficiency: Determined by simultaneous inulin, creatinine and 125iothalamate clearance | |
| JP3278661B2 (en) | Anticoagulant composition | |
| DE69619982T2 (en) | STABILIZED STANDARDS AND CALIBRATORS | |
| US20200096500A1 (en) | Method for measuring carbohydrate metabolism ability, and composition for use in said method | |
| JP2681244B2 (en) | Analytical method for urinary dissolved components | |
| Whiting et al. | Patterns of N-acetyl-β-d-glucosaminidase excretion after renal transplantation | |
| ES2656092T3 (en) | Composition and use of substances for in vitro stabilization of glucose, lactate and homocysteine in blood | |
| US5925570A (en) | Method of measuring metals in samples of living body | |
| JPH06100606B2 (en) | Method for preventing reduction of glucose content in collected blood | |
| JP2603576B2 (en) | How to save cells in urine | |
| CN112098171A (en) | Preparation method of urine chemical analysis quality control product | |
| EP3888694A1 (en) | Preparations of meta-iodobenzylguanidine and precursors thereof | |
| Calişkan et al. | Effect of anticoagulants on plasma homocysteine determination | |
| EP0592674B1 (en) | Method of assaying metal present in biological specimen and reagent therefor | |
| Krishna et al. | Urinary N-acetyl-β-d-glucosaminidase and aminopeptidase N in the diagnosis of graft rejection after live donor renal transplantation | |
| JP2628340B2 (en) | Method for stabilizing insulin component in blood | |
| JP4848555B2 (en) | Preservative composition for urine | |
| Wilson et al. | Comparison of serum iohexol clearance and plasma creatinine clearance in clinically normal horses | |
| JPH05164758A (en) | Stabilizing method for saccharide in blood sample | |
| Satoh et al. | A method for estimating the glomerular filtration rate in conscious monkeys | |
| JPH0778502B2 (en) | Method for preserving cells in urine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 19950124 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080808 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080808 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090808 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100808 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100808 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110808 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120808 Year of fee payment: 15 |
|
| LAPS | Cancellation because of no payment of annual fees |